Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 73–96 of 175
PX578, a first-in-class small molecule activator of mitochondrial DNA polymerase gamma, demonstrated preclinical efficacy in restoring mitochondrial DNA levels and cellular energy production across multiple POLG disease models. The compound addresses the underlying genetic defect in mitochondrial DNA depletion syndromes, for which no disease-modifying treatments currently exist.
BGE-102, an oral NLRP3 inhibitor, demonstrated rapid and substantial reductions in high-sensitivity C-reactive protein (85–86% median reduction) and inflammatory markers in a Phase 1 trial, with 87–93% of treated participants normalizing hsCRP levels and no serious adverse events reported. This early evidence suggests a therapeutic approach to systemic inflammation that may have relevance to age-related disease prevention.
Blarcamesine, a sigma-1 receptor agonist, demonstrated statistically significant improvements in motor function and reduced alpha-synuclein pathology in a preclinical Parkinson's disease model. The mechanism appears to engage underlying disease processes through modulation of cellular stress responses and protein homeostasis rather than symptomatic relief alone, with implications for disease-modifying approaches in neurodegeneration.
Novo Nordisk's $2.1 billion partnership with Vivtex aims to convert injectable obesity and diabetes medications into oral formulations, addressing a critical gap between drug efficacy and real-world adherence. The collaboration targets peptide therapeutics that are difficult to deliver orally while maintaining bioavailability, signaling that the obesity treatment landscape is shifting from efficacy metrics toward practical administration and sustained patient compliance.
As GLP-1 drug prices fall through government programs and compounded alternatives, the FDA warns of safety risks in unapproved formulations—including dosing errors, improper storage, and hospitalizations. The accessibility gains must be weighed against supply chain integrity and long-term health outcomes that depend on consistent, verified dosing.
Cognito Therapeutics presented clinical and biomarker data supporting Spectris, a non-invasive neurostimulation therapy using synchronized light and sound to modulate gamma frequency brain waves in Alzheimer's disease. Prior studies showed preserved brain structure, slowed cognitive decline, and reduced atrophy compared with controls, with favorable safety profiles and no amyloid-related imaging abnormalities.
Neuraly has initiated a Phase 2 trial (TAG-MS) evaluating pegsebrenatide, a GLP-1 receptor agonist, in approximately 120 patients with progressive multiple sclerosis. The study measures brain volume changes and neurological markers over 96 weeks, building on preclinical evidence suggesting the drug modulates neuroinflammation and protects neural tissue.
Celularity licensed its placental-derived biomaterials portfolio for up to $35 million in non-dilutive capital, allowing the company to redirect resources toward cell therapies targeting senescence, inflammation, and tissue degeneration. This repositioning reflects a strategic shift from broad biomaterials commercialization to targeted longevity interventions.
Danegaptide, an oral small molecule in Phase 1b trials, demonstrated tolerability and early clinical activity in 24 patients with diabetic retinopathy, showing reduced vascular leakage and macular edema over four weeks. The mechanism—stabilizing retinal vasculature against glucose-induced capillary breakdown—addresses a primary pathology in diabetic eye disease, with advancement to Phase 2 planned.
NeuroSense secured Brazilian patent protection for PrimeC, a fixed-dose combination of ciprofloxacin and celecoxib designed for neurodegenerative diseases including ALS and Alzheimer's. The patent, valid through 2042, follows U.S. and Australian approvals and supports ongoing Phase 3 development based on positive Phase 2b results.
A Novos clinical trial demonstrated statistically significant reductions in systolic and diastolic blood pressure, improved lipid profiles, and favorable shifts in metabolic markers among adults over 40 following the company's integrated lifestyle and metabolic support program. These findings support multimodal intervention as an approach to reducing established cardiovascular risk factors associated with aging.
Zervimesine (CT1812) demonstrated an 86% slowing of neuropsychiatric symptom decline in dementia with Lewy bodies patients compared to placebo in Phase 2 testing. This result supports advancement to late-stage trials and suggests a potential disease-modifying mechanism for a condition with limited therapeutic options.
ImmunoBrain's anti-PD-L1 therapy (IBC-Ab002) demonstrated acceptable safety and tolerability in early Alzheimer's patients, with cerebrospinal fluid biomarkers suggesting potential protection against synaptic and neuronal decline. This represents a shift toward immune-based approaches for neurodegenerative disease, targeting the chronic immune suppression that characterizes aging.
Blarcamesine demonstrated a measurable correlation between MRI-detected preservation of brain volume and slowing of cognitive decline in early Alzheimer's disease, with particularly strong outcomes in a genetically defined subpopulation. Long-term data suggest a potential delay in functional deterioration of approximately 18 months over 33 months of treatment.
ACSS2, an enzyme that regulates histone acetylation, maintains the oligodendrocyte precursor cell pool essential for myelin formation. Acetate supplementation restores myelination capacity after aging or injury, suggesting a metabolic lever for preserving neural insulation and signal transmission across the lifespan.
A UK Biobank study of 272,500 participants links elevated blood tyrosine levels to reduced lifespan, with a stronger effect in men (approximately one year lost per standard deviation increase). Using Mendelian randomization to establish causality rather than mere association, the research suggests tyrosine acts as a causal factor in mortality risk, independent of phenylalanine.
Obicetrapib, a CETP inhibitor, demonstrates cardiovascular benefits and potential neuroprotective effects against Alzheimer's disease—outcomes that distinguish it from four previous compounds in this drug class. The mechanism addresses both systemic lipid metabolism and cerebral amyloid pathology, making it relevant to multi-system longevity strategies.
Eli Lilly's $2.75 billion partnership with Insilico Medicine represents a strategic pivot toward AI-driven drug discovery aimed at aging-related pathology beyond current GLP-1 applications. The deal signals that large pharmaceutical companies now view longevity therapeutics as a commercially serious category worthy of substantial investment in discovery infrastructure.
Cognito Therapeutics raised $105 million to advance Spectris, a non-invasive device delivering synchronized visual and auditory stimulation designed to restore disrupted neural oscillations in Alzheimer's disease. Prior feasibility data showed slowed cognitive decline and 69% reduction in brain volume loss, with a 673-participant pivotal trial now fully enrolled and expected to yield results that could support regulatory submission in 2027.
PrimeC, a combination of two FDA-approved drugs in extended-release formulation, demonstrated a 14.7-month median survival improvement in ALS patients (36.3 months versus 21.4 months with placebo), with a 65% reduction in mortality risk after adjustment for baseline factors. This represents a clinically meaningful survival benefit in a neurodegenerative disease with limited therapeutic options.
Niagen Bioscience reported 30% year-over-year sales growth to $129.4 million in 2025, with net income more than doubling and gross margins expanding 250 basis points. The growth was driven by increased Tru Niagen product sales and ingredient revenue, supported by e-commerce expansion and market penetration.
GSK acquired Montreal-based 35Pharma for $950 million, gaining HS235, a targeted pulmonary hypertension candidate that addresses vascular dysfunction while showing early signals of metabolic benefit—fat-selective weight loss, preserved muscle, and improved insulin sensitivity. The drug represents a shift toward precision mechanisms that reduce side-effect burden in chronic disease management.
MZE829, an APOL1 inhibitor, demonstrated a 35.6% mean reduction in urinary albumin excretion at 12 weeks in APOL1-mediated kidney disease, with substantially larger reductions in focal segmental glomerulosclerosis (61.8%) and non-diabetic AMKD (48.6%). The compound was well tolerated with no serious adverse events, positioning it as a potential therapeutic for progressive kidney disease across multiple etiologies.
The FDA granted Fast Track Designation to 4P004, a GLP-1 analog designed for direct injection into the knee joint to treat osteoarthritis with inflammation in patients who have failed two prior drug therapies. The designation accelerates regulatory review for a candidate positioned as the first disease-modifying treatment targeting underlying joint degradation rather than symptoms alone.
